For nearly half of people diagnosed with lung cancer, immunotherapy can slow the disease but not stop it. Funded through a $4 million joint investment from the Canadian Cancer Society (CCS) and the Weston Family Foundation, a new clinical trial aims to change that.
Venetoclax and HMA-based Therapies for the Treatment of Older and Unfit Adults with Newly Diagnosed FLT3-mutated AML: A myeloMATCH Treatment Trial
VIGOR: Vorasidenib as Maintenance Treatment after First-line Chemoradiotherapy in IDH-mutant Grade 2 or 3 Astrocytoma
Autologous Stem Cell Transplant in Peripheral T Cell Lymphoma that Achieved a First Complete Remission (CR1) Following Induction Therapy (PTCL-STAT)
Lanreotide for the Prevention of Postoperative Pancreatic Fistula
A new survey study SC32S, collecting sociodemographic data from clinical trial participants, has now opened across Canada. This study will help researchers understand the feasibility of using a survey to gather information about trial participants’ backgrounds and everyday lives.
Phase II Trial of ASTX727 and Venetoclax Compared with ASTX727, Venetoclax, and Enasidenib for New Diagnosed Older Adults with IDH2 Mutant AML - A myeloMATCH Substudy
Eradicating MRD in Patients with AML prior to Stem Cell Transplant (ERASE)
Investigating Precision Medicine in the Adjuvant setting: a phase III Clinical Trial in Biliary tract cancer (SAFIR IMPACT BTC)
LUNA-2: LND101 in Unresectable Non-Small Cell Lung Cancer: A Randomized Phase II Trial
RAINBO-ORANGE: Treatment of Endometrial Cancer Based On Molecular Features
Delayed Reduced Volume and Dose Elective Radiotherapy (REVERT) in Patients with HNSCC
The next CCTG Clinical Research Associate (CRA) Lunch and Learn training session will be on Wednesday Jun 24th, 2025, at 12 pm ET, covering the top
CCTG is currently recruiting for a Regulatory Affairs Team Leader and a Cancer Research Monitor/Auditor to join our central offices at Queen's University in Kingston Ontario.
A new nation-wide study examines how COVID-19 is impacting cancer patients and survivors
March 12, 2021 By Jennifer Friesen
There’s no question that 2020 was a challenging year. Today, the effects of COVID-19 continue to echo around the world, impacting people’s lives, livelihoods and social connections.
In addition to navigating all this global uncertainty, an estimated 225,000 Canadians also faced a cancer diagnosis last year.
Evaluating the Indirect Costs of Care Associated with Salvage Chemotherapy for Relapsed and Refractory Aggressive-Histology Lymphoma: A Subset Analysis of the Canadian Cancer Trials Group (CCTG) LY12 Clinical Trial" has been published in Current Oncology and is available online: https://www.mdpi.com/1718-7729/28/2/119
It is official we are going virtual so save the dates April 22 – 25!
Two new fellowship opportunities from the University of British Columbia and BC Cancer: Glaxo Smith Kline Clinical Research Fellowship in Medical Oncology - Gynecologic Malignancies and the Miller Mindell Fellowship Gynecologic Oncology Research Fellowship
CommNETs hosted a virtual research workshop 10, 11, 16 and 17 February 2021 including a main conference event and five satellite project working group sessions. Thanks to the strong engagement of CommNETs collaborators, progress was made for planned work on existing projects and advancement of new ideas. CommNETs relies on the commitment of colleagues and partners to connect and lead research, and the continued collective effort of this group was evident through the excellent participation at the 2021 Virtual Research Workshop.
ExCELLirate Canada, led by the Canadian Cancer Trials Group (CCTG) at Queen’s University, has received $5,187,685 to develop a national research platform to coordinate the development of new cancer cell therapies. This will be a comprehensive national research, development and testing platform that will benefit patients, healthcare providers, and industry by ensuring Canadian cell therapy innovations are safely, cost effectively and efficiently manufactured.
